Emcure Pharmaceuticals Ltd and Sanofi India Ltd on Wednesday said they have entered into an exclusive distribution and promotion agreement for the latter's

埃姆库尔制药公司赛诺菲印度在周三表示，他们已经就后者的产品签订了独家分销和推广协议。

oral anti-diabetic products

口服抗糖尿病产品

in India with immediate effect.

在印度立即生效。

Under the agreement, Emcure will exclusively distribute and promote Sanofi India's OAD (oral anti-diabetic) range of products that include brands like Amaryl and Cetapin, the two companies said in a joint statement.

根据协议，Emcure将独家分销并推广赛诺菲印度的OAD（口服抗糖尿病）系列产品，包括Amaryl和Cetapin等品牌，两家公司在联合声明中表示。

Sanofi India will continue to own and manufacture these brands across its plants in India and internationally, it added.

赛诺菲印度公司补充说，将继续在印度和国际上的工厂拥有和生产这些品牌。

'With our strong distribution network in India, Sanofi's trusted oral anti-diabetic medicines will be available to more patients who need them,' Emcure Pharmaceuticals CEO and MD Satish Mehta said.

“凭借我们在印度的强大分销网络，赛诺菲值得信赖的口服抗糖尿病药物将提供更多给需要的患者，”埃姆库尔制药公司首席执行官兼董事总经理萨蒂什·梅赫塔表示。

Further, he said, 'This collaboration complements our existing diabetes portfolio, creating a comprehensive offering for the millions living with diabetes and supporting better diabetes care across the country.'

此外，他表示：“这次合作补充了我们现有的糖尿病产品组合，为数百万糖尿病患者提供了全面的服务，并支持在全国范围内提供更好的糖尿病护理。”

Live Events

现场活动

Similarly, Sanofi General Manager Pharma Southeast Asia and India & MCO Lead, Eric Mansion, said, 'With Emcure's wide and deeply penetrated presence across India, we are confident of tapping into the full growth potential of our best-in-class and industry-leading OADs Amaryl and Cetapin. This partnership will truly benefit both - the patients who need them and the healthcare professionals who trust and prescribe them.'.

同样，赛诺菲东南亚和印度制药总经理兼MCO负责人埃里克·曼森表示：“凭借Emcure在印度广泛而深入的市场覆盖，我们有信心充分挖掘我们一流的行业领先的口服降糖药Amaryl和Cetapin的增长潜力。这一合作将真正使患者和信任并开具这些药物的医疗专业人员双方受益。”